Drug Profile

Human leukocyte antigen A 01:01 TSC 102 - TScan Therapeutics

Alternative Names: TSC 102 HLA-A*01:01; TSC-102-A01

Latest Information Update: 12 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TScan Therapeutics
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

26 Feb 2026 TScan Therapeutics plans a phase I trial in second half of 2026
26 Feb 2026 Preclinical trials in Haematological malignancies in USA (Parenteral)
26 Feb 2026 US FDA approves IND application for Human leukocyte antigen A 01:01 TSC 102 in Haematological malignancies

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com